MX2022006701A - Terapia combinada para el tratamiento de neoplasias malignas. - Google Patents

Terapia combinada para el tratamiento de neoplasias malignas.

Info

Publication number
MX2022006701A
MX2022006701A MX2022006701A MX2022006701A MX2022006701A MX 2022006701 A MX2022006701 A MX 2022006701A MX 2022006701 A MX2022006701 A MX 2022006701A MX 2022006701 A MX2022006701 A MX 2022006701A MX 2022006701 A MX2022006701 A MX 2022006701A
Authority
MX
Mexico
Prior art keywords
combination therapy
treating malignancies
treating
aml
malignancies
Prior art date
Application number
MX2022006701A
Other languages
English (en)
Inventor
Samuel V Agresta
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of MX2022006701A publication Critical patent/MX2022006701A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Se proporcionan métodos y composiciones para tratar la AML en pacientes portadores de una mutación de IDH2 usando una combinación de un inhibidor de una enzima IDH2 mutante y una terapia de inducción y consolidación para tratar la AML.
MX2022006701A 2015-10-15 2018-04-13 Terapia combinada para el tratamiento de neoplasias malignas. MX2022006701A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562242256P 2015-10-15 2015-10-15
US201562255194P 2015-11-13 2015-11-13

Publications (1)

Publication Number Publication Date
MX2022006701A true MX2022006701A (es) 2022-07-12

Family

ID=57208385

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018004595A MX2018004595A (es) 2015-10-15 2016-10-14 Terapia combinada para el tratamiento de neoplasias malignas.
MX2022006701A MX2022006701A (es) 2015-10-15 2018-04-13 Terapia combinada para el tratamiento de neoplasias malignas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018004595A MX2018004595A (es) 2015-10-15 2016-10-14 Terapia combinada para el tratamiento de neoplasias malignas.

Country Status (15)

Country Link
US (2) US10905692B2 (es)
EP (2) EP3362057A1 (es)
JP (2) JP2018534288A (es)
KR (1) KR20180063125A (es)
CN (1) CN108366980A (es)
AU (1) AU2016340087C1 (es)
BR (1) BR112018007304A2 (es)
CA (1) CA3001599A1 (es)
CL (1) CL2018000927A1 (es)
EA (1) EA201890968A1 (es)
IL (1) IL258269A (es)
MX (2) MX2018004595A (es)
SG (1) SG10201912886XA (es)
WO (1) WO2017066599A1 (es)
ZA (1) ZA201802088B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2962943A1 (en) 2014-09-29 2016-04-07 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2016126798A1 (en) 2015-02-04 2016-08-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
JP6895956B2 (ja) 2015-10-15 2021-06-30 セルジーン コーポレイション 悪性腫瘍を治療するための併用療法
WO2018048847A1 (en) 2016-09-07 2018-03-15 Celgene Corporation Tablet compositions
WO2018204787A1 (en) 2017-05-05 2018-11-08 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
CA3069558A1 (en) * 2017-07-09 2019-01-17 Biosight Ltd. Combination cancer therapy
US10980788B2 (en) * 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
WO2020092915A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
US20220017490A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
WO2021097160A1 (en) 2019-11-14 2021-05-20 Celgene Corporation Pediatric formulations for treatment of cancer
CN111087408B (zh) * 2020-01-03 2021-04-02 浙江大学 一种大环结构的idh2突变体抑制剂及其医药用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT998271E (pt) 1997-06-06 2005-10-31 Depomed Inc Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20120121515A1 (en) 2009-03-13 2012-05-17 Lenny Dang Methods and compositions for cell-proliferation-related disorders
CA2793836C (en) * 2009-10-21 2020-03-24 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
CN115536635A (zh) 2012-01-06 2022-12-30 法国施维雅药厂 治疗活性化合物及其使用方法
CN105492435B (zh) 2013-07-11 2018-06-29 安吉奥斯医药品有限公司 作为idh2突变体抑制剂的化合物
EP3932408A1 (en) 2013-08-02 2022-01-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015018060A1 (en) 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
CA2962943A1 (en) 2014-09-29 2016-04-07 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2016126798A1 (en) 2015-02-04 2016-08-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3331866B1 (en) 2015-08-05 2023-07-26 Les Laboratoires Servier Methods of preparing a 6-heteroaryl-1,3,5-triazine-2,4-diol and a 6-heteroaryl-1,3,5-triazine-2,4-diamine
JP6895956B2 (ja) 2015-10-15 2021-06-30 セルジーン コーポレイション 悪性腫瘍を治療するための併用療法
JP6892448B2 (ja) 2015-12-04 2021-06-23 アジオス ファーマシューティカルズ， インコーポレイテッド 悪性腫瘍の処置の方法
JP6856657B2 (ja) 2016-02-26 2021-04-07 アジオス ファーマシューティカルズ， インコーポレイテッド 血液学的悪性疾患および固形腫瘍の処置のためのｉｄｈ１阻害剤

Also Published As

Publication number Publication date
BR112018007304A2 (pt) 2018-10-23
IL258269A (en) 2018-05-31
SG10201912886XA (en) 2020-02-27
EP3362057A1 (en) 2018-08-22
US20180311249A1 (en) 2018-11-01
JP2018534288A (ja) 2018-11-22
EA201890968A1 (ru) 2018-09-28
KR20180063125A (ko) 2018-06-11
ZA201802088B (en) 2021-07-28
WO2017066599A1 (en) 2017-04-20
US10905692B2 (en) 2021-02-02
CN108366980A (zh) 2018-08-03
MX2018004595A (es) 2019-07-04
EP4147692A1 (en) 2023-03-15
CL2018000927A1 (es) 2018-09-14
AU2016340087C1 (en) 2022-08-18
AU2016340087B2 (en) 2022-05-12
JP2021130682A (ja) 2021-09-09
US20210386749A1 (en) 2021-12-16
CA3001599A1 (en) 2017-04-20
AU2016340087A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
MX2022006701A (es) Terapia combinada para el tratamiento de neoplasias malignas.
MX2018004599A (es) Terapia de combinacion para el tratamiento de neoplasias malignas.
ZA201803162B (en) Combination therapy for treating malignancies
MX2018004586A (es) Terapia de combinacion para tratar tumores malignos.
MX2018006831A (es) Metodos de tratamiento de neoplasias malignas.
MX2018010261A (es) Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
MY161237A (en) Combination therapy comprising a cdk4/6 inhibitor and a p13k inhibitor for use in the treatment of cancer
MX2019007648A (es) Composiciones y metodos para la induccion de celulas t cd8+.
MX2020003939A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
MX364438B (es) Inhibidores covalentes de kras g12c.
CL2015002807A1 (es) Terapia de combinación
MX369691B (es) Inhibidores de glutaminasa y métodos de empleo.
MX2018006152A (es) Metodos para el tratamiento de cancer utilizando inhibidores b-raf e inhibidores de punto de control inmunologico.
MX2017003797A (es) Macrociclos peptidomimeticos y usos de los mismos.
MY190411A (en) Improved uricase sequences and methods of treatment
MX2016015161A (es) Metodos de tratamiento de cancer de mama luminal a positivo para pr con inhibidor de pi3k, pictilisib.
MY201580A (en) Use of ezh2 inhibitor combined with btk inhibitor in preparing drug for treating tumor
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MY176599A (en) Treatment of prostate cancer with tor kinase inhibitors
MX2018011875A (es) Reprogramacion cardiaca directa mejorada.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
WO2018081817A3 (en) Targeting microrna-101-3p in cancer therapy
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
MX2019001337A (es) Métodos para tratar y prevenir efectos secundarios por tratamiento de cáncer.